Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.

Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG

Diabetes care1 Jun 1998Cited by 66 (Europe PMC)

PMID9614619DOI10.2337/diacare.21.6.987PepBankPUB-09614619

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialSafety outcome
In insulin-treated type 2 diabetes, hypoglycemia incidence was similar across pramlintide and placebo groups.
In plain wordsIn insulin-treated type 2 diabetes, low blood sugar occurred at similar rates with pramlintide and placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycemia
Study
n = 203
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
The incidence of hypoglycemia was similar in all treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461913
02HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum fructosamine
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Serum fructosamine reduction
17.5 mumol/l
pramlintide 30 micrograms q.i.d.
Serum fructosamine reduction
3.5 mumol/l
placebo
Source sentences
Summary
Statistically significant reductions in serum fructosamine concentrations were observed in the pramlintide 30 micrograms q.i.d. group (17.5 +/- 4.9 mumol/l, P = 0.029), the pramlintide 60 micrograms t.i.d. group (24.1 +/- 4.9 mumol/l, P = 0.003), and the 60 micrograms q.i.d. group (22.6 +/- 4.1 mumo…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461901
03HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum fructosamine
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms t.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Serum fructosamine reduction
24.1 mumol/l
pramlintide 60 micrograms t.i.d.
Serum fructosamine reduction
3.5 mumol/l
placebo
Source sentences
Summary
Statistically significant reductions in serum fructosamine concentrations were observed in the pramlintide 30 micrograms q.i.d. group (17.5 +/- 4.9 mumol/l, P = 0.029), the pramlintide 60 micrograms t.i.d. group (24.1 +/- 4.9 mumol/l, P = 0.003), and the 60 micrograms q.i.d. group (22.6 +/- 4.1 mumo…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461902
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced fructosamine more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum fructosamine
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Serum fructosamine reduction
22.6 mumol/l
pramlintide 60 micrograms q.i.d.
Serum fructosamine reduction
3.5 mumol/l
placebo
Source sentences
Summary
Statistically significant reductions in serum fructosamine concentrations were observed in the pramlintide 30 micrograms q.i.d. group (17.5 +/- 4.9 mumol/l, P = 0.029), the pramlintide 60 micrograms t.i.d. group (24.1 +/- 4.9 mumol/l, P = 0.003), and the 60 micrograms q.i.d. group (22.6 +/- 4.1 mumo…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461903
05HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, the proportion with normalized fructosamine increased significantly within the pramlintide group.
In plain wordsIn insulin-treated type 2 diabetes, more patients had normal fructosamine after pramlintide treatment than at baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseFructosamine normalization
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms t.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
There were also statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at week 4 within the pramlintide 60 micrograms t.i.d. group and the 60 micrograms q.i.d. group.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461904
06HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, the proportion with normalized fructosamine increased significantly within the pramlintide group.
In plain wordsIn insulin-treated type 2 diabetes, more patients had normal fructosamine after pramlintide treatment than at baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseFructosamine normalization
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
There were also statistically significant shifts in the proportion of patients with an abnormal serum fructosamine concentration at baseline that normalized at week 4 within the pramlintide 60 micrograms t.i.d. group and the 60 micrograms q.i.d. group.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461905
07HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
HbA1c reduction
0.53%
pramlintide 30 micrograms q.i.d.
HbA1c reduction
0.27%
placebo
Source sentences
Summary
Consistent with the fructosamine results, there were statistically significant reductions in HbA1c in the pramlintide 30 micrograms q.i.d. group (0.53 +/- 0.07%, P = 0.0447), the pramlintide 60 micrograms t.i.d. group (0.58 +/- 0.07%, P < 0.0217), and the pramlintide 60 micrograms q.i.d. group (0.51…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461906
08HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms t.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
HbA1c reduction
0.58%
pramlintide 60 micrograms t.i.d.
HbA1c reduction
0.27%
placebo
Source sentences
Summary
Consistent with the fructosamine results, there were statistically significant reductions in HbA1c in the pramlintide 30 micrograms q.i.d. group (0.53 +/- 0.07%, P = 0.0447), the pramlintide 60 micrograms t.i.d. group (0.58 +/- 0.07%, P < 0.0217), and the pramlintide 60 micrograms q.i.d. group (0.51…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461907
09HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced HbA1c more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
HbA1c reduction
0.51%
pramlintide 60 micrograms q.i.d.
HbA1c reduction
0.27%
placebo
Source sentences
Summary
Consistent with the fructosamine results, there were statistically significant reductions in HbA1c in the pramlintide 30 micrograms q.i.d. group (0.53 +/- 0.07%, P = 0.0447), the pramlintide 60 micrograms t.i.d. group (0.58 +/- 0.07%, P < 0.0217), and the pramlintide 60 micrograms q.i.d. group (0.51…
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461908
10HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced total cholesterol more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced total cholesterol more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
60 micrograms t.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Total cholesterol reduction
8.4 mg/dl
pramlintide 60 micrograms t.i.d.
Total cholesterol reduction
1.2 mg/dl
placebo
Source sentences
Summary
Total cholesterol concentrations were also statistically significantly reduced in both the pramlintide 60 micrograms t.i.d. group (8.4 mg/dl, P < 0.01) and 60 micrograms q.i.d. group (10.5 mg/dl, P < 0.01) compared with placebo (1.2 mg/dl).
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461909
11HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced total cholesterol more than placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced total cholesterol more than placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
60 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Total cholesterol reduction
10.5 mg/dl
pramlintide 60 micrograms q.i.d.
Total cholesterol reduction
1.2 mg/dl
placebo
Source sentences
Summary
Total cholesterol concentrations were also statistically significantly reduced in both the pramlintide 60 micrograms t.i.d. group (8.4 mg/dl, P < 0.01) and 60 micrograms q.i.d. group (10.5 mg/dl, P < 0.01) compared with placebo (1.2 mg/dl).
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461910
12HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, body weight decreased nonsignificantly during pramlintide treatment.
In plain wordsIn insulin-treated type 2 diabetes, weight decreased during pramlintide treatment, but the trend was not significant.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
60 micrograms t.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
Body weight decreased in both of the pramlintide 60 micrograms groups, but the trend did not achieve statistical significance.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461911
13HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, body weight decreased nonsignificantly during pramlintide treatment.
In plain wordsIn insulin-treated type 2 diabetes, weight decreased during pramlintide treatment, but the trend was not significant.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
60 micrograms q.i.d. · subcutaneous · 4 weeksAs given in this study (human).
Source sentences
Summary
Body weight decreased in both of the pramlintide 60 micrograms groups, but the trend did not achieve statistical significance.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of 4 weeks of subcutaneous administration of pramlintide, a synthetic analog of human amylin, on metabolic control in patients with type 2 diabetes using insulin.
Summary · context
Serum fructosamine, HbA1c, and fasting plasma lipids were measured in 203 patients in a randomized double-blind placebo-controlled parallel-group multicenter trial using doses of 30 micrograms q.i.d., 60 micrograms t.i.d., and 60 micrograms q.i.d.
Report a problemFND-0961461912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.